Catalyst Wire Dossier Catalyst Wire Dossier

IGALMI

DEXMEDETOMIDINE · BioXcel Therapeutics, Inc.
Drug timelines are a Plus or Pro feature.

4 regulatory and trial events tracked for IGALMI, covering 2022-04-05 to 2026-01-02. Get the full timeline:

Most recent: Clinical Trial Update: Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disorder [Phase 4]

See pricing